Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, BeyondSpring Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Ignyta, Lilly, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Community Practice Connections™: 18th Annual International Lung Cancer Congress®

Release Date: October 31, 2017
Expiration Date: October 31, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: 18th Annual International Lung Cancer Congress® consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, AstraZeneca, BeyondSpring Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Ignyta, Lilly, Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, and Takeda Oncology.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

CME/CE Activity Table of Contents

  • Module 1: A Patient With Unresctable, Stage III NSCLC
  • Module 2: A Patient With Advanced Lung Adenocarcinoma
  • Module 3: A Patient With Advanced, Squamous NSCLC
  • Module 4: A Patient With ALK-rearranged NSCLC
  • Module 5: A Patient With EGFR Mutation-Positive NSCLC

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists, nurse practitioners (NPs), nurses, and physician assistants (PAs) involved in the treatment and management of patients with lung cancers. Pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Delineate testing strategies for the diagnosis and identification of biomarkers which can be used to facilitate clinical decision making in multiple lines of lung cancer care
  • Explain evolving treatment strategies for early-stage and locally advanced lung cancer
  • Determine optimized sequencing strategies for the management of advanced lung cancer based on clinical data sets, performance status, and tumor characteristics
  • Assess current data sets and ongoing clinical trials evaluating single agent and combination immunotherapeutic approaches
  • Place recent clinical trial results on chemotherapeutic, targeted, and immunotherapeutic strategies in the context of current treatment standards and evolving paradigms in the management of lung cancer
  • Explain the current status of cooperative group trials and methods to facilitate participation in clinical trials that are assessing emerging strategies to treat lung cancer

Faculty, Staff, and Planners' Disclosures

Faculty

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosure: Grant Research Support: AstraZeneca/Medi, Bristol-Myers Squib, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis; Consultant: Ariad, AstraZeneca, Boehringer-Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Merck, Mirati, Novartis, Pfizer

Sarah B. Goldberg, MD, MPH
Assistant Professor of Internal Medicine
Medical Oncology
Yale Cancer Center
New Haven, CT
 

Disclosure: Grant Research Support: AstraZeneca; Other: Advisory Board for AstraZeneca

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosure: Grant Research Support: Genentech, Merck; Consultant: AstraZeneca, Eli Lilly, Genentech/Roche, Merck, Pfizer

Christine M. Lovly, MD, PhD
Assistant Professor of Medicine, Division of Hematology-Oncology
Assistant Professor of Cancer Biology
Vanderbilt University School of Medicine
Vanderbilt Ingram Cancer Center
Nashville, TN

Disclosure: Consultant: Novartis, Pfizer, Ariad, Genoptix, AstraZeneca, Takeda

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse™ Recap


1 of 3

PER Pulse™ Recap

Moving Lung Cancer Immunotherapy into Earlier Stages

The 18th Annual International Lung Cancer Congress®, held July 27-29, 2017, was planned to convey state-of-the-art multidisciplinary approaches for the care of patients with lung cancer, as well as to provide physicians with an update on new approaches and agents that will change the management of patients with lung cancer. This first of 3 PER Pulse™ Recaps from the International Lung Cancer Congress® focuses on developments in immunotherapy in earlier stages of lung cancer.

Initially approved for patients with metastatic, platinum-pretreated, non–small cell lung cancer (NSCLC), immunotherapy has become established in the first-line setting and has also demonstrated clinical benefit in stage III NSCLC. In October 2016, single-agent pembrolizumab was approved as first-line therapy in patients with advanced NSCLC and a PD-L1 expression level of ≥50% based on the phase III KEYNOTE-024 trial, which compared single-agent pembrolizumab to standard platinum-based chemotherapy. In May 2017, the combination of pembrolizumab and carboplatin/pemetrexed received accelerated approval for first-line therapy of patients with nonsquamous NSCLC regardless of PD-L1 expression levels. More recently, the phase III PACIFIC trial randomized patients with unresectable stage III NSCLC who did not experience disease progression following concurrent chemoradiation therapy to receive either durvalumab or placebo. The co-primary endpoint of progression-free survival was superior in the durvalumab arm (16.8 vs 5.6 months; HR, 0.52; P <.001), and the study continues to mature for the endpoint of overall survival.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 18th Annual International Lung Cancer Congress.®

2 of 3
PER Pulse™ Recap

Changing Standards of Care for ALK-Rearranged NSCLC

The 18th Annual International Lung Cancer Congress®, held July 27-29, 2017, was planned to convey state-of-the-art multidisciplinary approaches for the care of patients with lung cancer, as well as to provide physicians with an update on new approaches and agents that will change the management of patients with lung cancer. This second of 3 PER Pulse™ Recaps from the International Lung Cancer Congress® focuses on recent data and approvals for patients with non–small cell lung cancer (NSCLC) and rearrangements in the anaplastic lymphoma kinase (ALK) gene.

Crizotinib has been the first-line standard of care for patients with ALK-rearranged NSCLC; however, other agents have demonstrated activity in this setting. Recently, the phase III ASCEND-4 trial compared ceritinib with platinum-based chemotherapy, meeting the primary endpoint of progression-free survival (PFS) and leading to approval in May 2017. The phase III global ALEX trial compared alectinib to crizotinib, with alectinib demonstrating superiority in the primary endpoint of PFS. The 12-month PFS was 68% with alectinib, compared with 49% with crizotinib (HR, 0.47; P <.001). Alectinib is under priority review, with a decision expected in November 2017. Finally, for patients whose disease progresses during crizotinib therapy or who become intolerant of crizotinib, the next-generation ALK inhibitor brigatinib was granted accelerated approval in April 2017.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 18th Annual International Lung Cancer Congress.®

3 of 3
PER Pulse™ Recap

Advances in EGFR and BRAF Inhibition in Lung Cancer

The 18th Annual International Lung Cancer Congress®, held July 27-29, 2017, was planned to convey state-of-the-art multidisciplinary approaches for the care of patients with lung cancer, as well as to provide physicians with an update on new approaches and agents that will change the management of patients with lung cancer. This third of 3 PER Pulse™ Recaps from the International Lung Cancer Congress® focuses on new approaches for patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) or BRAF gene.

First-line standards of care for patients with EGFR mutation-positive NSCLC include erlotinib, afatinib, and gefitinib; however, next-generation EGFR inhibitors are being developed in this setting. The phase III FLAURA trial randomized patients with EGFR mutation-positive NSCLC to first-line therapy with osimertinib or standard approaches (erlotinib or gefitinib). Progression-free survival (PFS) was superior in the osimertinib arm (18.9 vs 10.2 months; HR, 0.46; P .0001), and osimertinib was granted breakthrough therapy designation in October 2017. Earlier in 2017, results of the phase III ARCHER 1050 study were presented, in which dacomitinib demonstrated superior PFS compared with gefitinib (14.7 vs 9.2 months, HR, 0.59; P <.0001).

Inhibition of BRAF/MEK is a proven therapeutic approach in patients with melanoma. In June 2017, the combination of dabrafenib and trametinib was approved for patients with BRAF V600E-positive NSCLC. This approval was based on a phase II trial examining the combination of dabrafenib plus trametinib, with separate cohorts for newly diagnosed patients and for patients with platinum-pretreated NSCLC. The primary endpoint of overall response rate was similar (63%-64%) in both cohorts.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 18th Annual International Lung Cancer Congress.®







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
2728293031
Filter By